

	Total N=493	MHR <17,68 N=278	MHR ≥17,68 N=215	P value
Age (Years)	63,03±10,88	63,33±10,79	62,65±11,00	0,490*
Follow-up time (Months)	48 (26-73)	48,5 (27,75- 70,25)	48 (22-76)	0,891
Male gender	353 (71,6%)	183 (65,8%)	170 (79,1%)	0,001
Mortality	113 (22,9%)	43 (15,5%)	70 (32,6%)	<0,001
Hypertension	172 (34,9%)	90 (32,4%)	82 (38,1%)	0,183
Diabetes mellitus	143 (29%)	73 (26,3%)	70 (32,6%)	0,126
Hyperlipidaemia	31 (6,3%)	14 (5%)	17 (7,9%)	0,193
Smoker	132 (26,8%)	61 (21,9%)	71 (33%)	0,006
Chronic renal disease	27 (5,5%)	12 (4,3%)	15 (7%)	0,198
Family history	28 (5,7%)	15 (5,4%)	13 (6%)	0,757
Cerebrovascular events	13 (2,6%)	6 (2,2%)	7 (3,3%)	0,451
LVEF	50 (40-60)	55 (45-60)	50 (40-60)	0,016
Symptomatology				
Asymptomatic	1 (0,2%)	1 (0,4%)	0	
SAP	230 (46,7%)	144 (51,8%)	86 (40%)	
USAP	120 (24,3%)	65 (23,4%)	55 (25,6%)	0,035**
NSTEMI	126 (25,6%)	58 (20,9%)	68 (31,6%)	
STEMI	16 (3,2%)	10 (3,6%)	16 (3,2%)	
Clinical approach				
Medical treatment	104 (21,1%)	54 (19,4%)	50 (23,3%)	
PCI	254 (51,5%)	152 (54,7%)	102 (47,4%)	0,454**
Failed CTO intervention	61 (12,4%)	32 (11,5%)	29 (13,5%)	
CABG	74 (15%)	40 (14,4%)	34 (15,8%)	